The factors that influence utilization of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HCT) among medically fit older patients with advanced myelodysplastic syndromes (MDS) are largely unknown. The MDS Transplant-Associated Outcomes (MDS-TAO) study is an ongoing prospective observational study at the Dana-Farber Cancer Institute and Massachusetts General Hospital that enrolls transplant-eligible fit patients aged 60-75 years with advanced MDS and follows them through RIC HCT vs non-HCT treatment. In this analysis of 127 patients enrolled from May 2011 to June 2014, we examined the influence of age, gender, cytogenetics, International Prognostic Scoring System (IPSS) category, performance status, distance from HCT center and baseline patient-reported quality of life (QOL) from the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) on the likelihood of receiving RIC HCT using competing risk regression modeling. With a median follow-up of 16 months, 44 patients (35%) had undergone RIC HCT. In multivariable analyses, age (hazard ratio (HR) 0.87 per year, 95% confidence interval (CI): 0.81-0.92, P o 0.001) and higher IPSS (intermediate-2/high; HR 2.29, 95% CI: 1.25-4.19, P = 0.007) were significantly predictive of receipt of RIC HCT; neither global QOL score nor any QOL subscales scores were predictive. These data suggest that baseline patient-reported QOL has little influence on the decision to undergo RIC HCT for older patients with advanced MDS.
INTRODUCTION
The myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders that are characterized by peripheral cytopenias, bone marrow failure and a variable risk of progressing to AML.
1,2 MDS predominantly affects older patients, with a median age at diagnosis of at least 65 years. 1, 2 While the prognosis of patients with MDS is heterogeneous, patients with advanced disease have poor outcomes without disease-modifying treatment, with a median overall survival of about 1 year. 3, 4 Moreover, patient-reported quality of life (QOL) is highly variable as some patients are asymptomatic, whereas others are heavily affected by fatigue, infections, bleeding and other symptoms. [4] [5] [6] [7] Allogeneic hematopoietic stem cell transplantation (HCT) is currently the only potentially curative therapy for MDS. [8] [9] [10] [11] Unfortunately, many patients are ineligible for HCT given their advanced age or medical comorbidities. 1, 12 With the advent of reduced-intensity conditioning (RIC), an increasing number of older patients with MDS have been considered for this potentially curative therapy. [13] [14] [15] Indeed, in a recent Markov decision analysis, patients older than 60 years with high-risk MDS were shown to have a modest survival advantage with early use of HCT compared with the use of hypomethylating agents. 16 Despite these encouraging results, concerns regarding the morbidity and mortality of RIC HCT have limited its application in this population.
Among older patients who have disease advanced enough to warrant HCT and who are thought to be medically fit to survive the procedure, the relative importance of factors influencing the decision to proceed with RIC HCT is essentially unknown. Candidate factors that likely impact this decision-making process include patient's age, disease course and severity, 17 QOL, patients' preferences with respect to the relative utility of being cured versus risk of transplant and burden of prolonged treatments, donor availability, and clinicians' perception of patients' QOL and functional status. Elucidating these factors is instrumental to address barriers to RIC HCT in this population with potentially curable disease, and to delineate important considerations that may be overlooked in the decision-making process. Patient-reported QOL is a multidimensional concept that measures patients' general health and well-being including their perception of their physical functioning, and emotional and social well-being. 18 Measurement of QOL is increasingly recognized as an important outcome in cancer trials and patient care, especially among patients with chronic and potentially life-threatening illnesses such as MDS. 19 It is also essential to understand pretreatment QOL as a context for treatment decision-making. Indeed, studies have shown that QOL scores before allogeneic HCT are independently associated with post-transplant mortality irrespective of performance status and medical comorbidities. [20] [21] [22] Moreover, while patients' and clinicians' perception of QOL may influence their decisions regarding pursuit of therapies, 22 the impact of baseline QOL on the likelihood of receiving allogeneic HCT for advanced MDS is not known.
We took advantage of an ongoing cohort to study the potential influence of patient-reported QOL on the decision to undergo HCT. The MDS Transplant-Associated Outcomes (MDS-TAO) study enrolls patients who are largely uniform in that they have advanced MDS, have minimal comorbidities and are thus 'transplant-eligible,' and have expressed that they are willing to be considered for RIC HCT. In this analysis, we sought to examine factors that influence the utilization of RIC HCT for this high-risk, HCT-eligible population. Moreover, we hypothesized that compromised patient-reported QOL at enrollment would be an important factor predicting the receipt of RIC HCT, as fit patients who were highly symptomatic might be more inclined to pursue aggressive treatment.
MATERIALS AND METHODS Participants
We recruited patients at the Dana-Farber Cancer Institute and the Massachusetts General Hospital, both in Boston, Massachusetts. Patients were aged 60 to 75 years with a diagnosis of MDS or related disorder (e.g., MDS/myeloproliferative neoplasm) who had disease advanced enough to warrant consideration for RIC HCT. 23 Patients had to also be physically 'fit' enough to undergo HCT as assessed by having an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2 and having adequate organ function to permit the procedure (serum bilirubin ⩽ 2.5 mg/dL; aspartate aminotransferase ⩽ 2.5 × the laboratory upper limit of normal; alanine aminotransferase ⩽ 2.5 × upper limit of normal; serum creatinine ⩽ 2.0 mg/dL; no record of uncontrolled pulmonary or cardiac disorders). We also excluded patients with other severe concurrent illness that in the judgment of the treating clinician would make the patient inappropriate for HCT. Finally, we excluded patients who had already undergone a formal donor search at the time of study entry, and those who had undergone any prior HCT.
Study design and procedures
We identified eligible patients with advanced MDS by screening new patients scheduled to be seen at the two participating centers. MDS patients who were not eligible were also followed in case they had a change in their clinical status (e.g., progression of disease) that would render them eligible. After informed consent, study participants completed a baseline demographic and QOL questionnaire; importantly, treating oncologists were not given access to these formal QOL results, but were free to ask any questions they wanted about QOL as part of their routine clinical encounter. The study was approved by the Office for Human Research Studies of the Dana-Farber/Harvard Cancer Center.
Outcomes
We abstracted patient-and disease-related variables along with follow-up survival data on all participants using the Dana-Farber/Harvard Cancer Center Leukemia Clinical Research Information System. Started in 2006, Clinical Research Information System includes most patients with leukemia, MDS and related disorders seen at the two participating centers, with detailed information regarding patients' demographics, ECOG performances status, comorbidities, disease-risk stratification, prior therapies and disease and survival status. For patients who stopped treatment at either center, permission was granted at enrollment to obtain records from local physicians. Of note, all patients who underwent HCT received RIC, as neither of the centers use non-myeloablative conditioning for the treatment of MDS.
We administered the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) to all participants to measure patient-reported QOL at the time of study enrollment. This took place before identifying any potential donors and consideration for HCT. The EORTC QLQ-C30 is a well-validated questionnaire measuring several domains of QOL including global health status, physical functioning, role functioning, cognitive functioning and fatigue. 26 The questionnaire has been validated for use in patients with cancer and has been previously used to measure QOL in patients with MDS. 18, 27 Statistical methods
We first used descriptive statistics to summarize patient and disease characteristics for all study subjects. We then estimated the cumulative incidence of time to HCT using a competing risk framework, reflecting time to death without undergoing HCT as a competing event. We defined time to HCT as the time from the date of obtaining informed consent to the date of stem cell infusion. We then examined potential factors that may influence receiving HCT in competing risk regression analyses. 28 Factors statistically significant (two-sided Po0.05) in univariable analysis were then entered into a multivariable model. For continuous variables (age, distance from transplant center and QOL scales), we checked tests of linear associations with outcomes; the linearity assumption was not violated for any of the variables. For cytogenetic categories, we used IPSS designations (good/intermediate/poor). 3 We also conducted additional exploratory analyses using dichotomization cutoffs for linear variables, and differences in time to HCT between individual leukemia providers or between individual HCT providers.
Given concerns that ECOG PS or IPSS designation may confound the relationship between QOL and the time to receipt of HCT, we examined the relationship between these potential confounders with the predictor of interest (QOL) and our outcome (time to HCT) in univariable and multivariable analyses. We also performed formal power calculations. Given the number of HCT events (N = 44), the SD of the QOL scores (~2.5 per 10 points), a type I error rate of 5% and power of 80%, the minimum hazard ratio that could be detected with this study cohort was 0.85 per 10 point difference in QOL scores (alternatively, 1/0.85 = 1.18). We conducted all statistical analyses using Stata 13.1 (StataCrop LP, College Station, TX, USA).
RESULTS

Participants characteristics
We enrolled 129 of 134 patients (96%) who met the eligibility criteria between May 2011 and June 2014 (five refused participation). For this analysis, we excluded an additional two patients who died within 1.5 months after enrollment, as we felt that this would not have given enough time for HCT. Table 1 depicts sociodemographic and clinical characteristics of the remaining 127 study participants. The median global QOL score was 67 and the median fatigue score was 33 (published medians are 67 and 33 for other cancers; 24 higher global QOL scores indicate superior QOL, whereas higher fatigue scores indicate worse fatigue; see Figure 1 ).
Receipt of allogeneic RIC HCT and cohort follow-up Of the 127 patients, 49 (39%) died during the follow-up period. The median follow-up among survivors was 16 months (range 2.2-40) from enrollment. Figure 2 depicts the cumulative incidence of receiving an allogeneic HCT, where death without transplant was a competing risk. Overall, 44 participants (35%) received an allogeneic RIC HCT, of whom 12 (27%) subsequently died. In the non-transplanted group (n = 83), 37 (45%) died during the follow-up period. The median follow-up time for patients alive and not yet transplanted (n = 46) was 15 months (range 2.2-39). The median time between QOL measurement (time of enrollment) and receipt of HCT for those who eventually underwent an allogeneic HCT was 4.3 months (range 1.5-19.1).
Factors predicting receipt of allogeneic HCT In univariable competing risks regression analysis to identify predictors for receipt of HCT, none of the major QOL domains of the EORTC QLQ-C30 (global health status, fatigue, physical functioning, role functioning or cognitive functioning) were significantly associated with the likelihood of receiving HCT (Table 2) . Moreover, when we dichotomized QOL scores for each domain, we did not detect any association between patients' QOL at enrollment and the likelihood of receiving HCT. Similarly, distance to HCT center, participants' gender and baseline ECOG performance status were not significantly associated with receipt of HCT (Table 2 ). In contrast, participants' age was inversely associated with receiving HCT (P o 0.001) and participants with poor cytogenetics (P = 0.01) and intermediate-2/high-risk IPSS (P = 0.004) were both more likely to receive HCT compared with those with good/intermediate cytogenetics and low/intermediate-1 risk IPSS disease, respectively.
Factors predicting receipt of allogeneic HCT Given the collinearity between IPSS and cytogenetics, we constructed two separate multivariable competing risks regression analyses to examine factors most likely to influence receipt of HCT (Table 3) . In the first model, younger age at study enrollment (P o 0.001) and intermediate-2/high IPSS (P ¼ 0.007) remained significant predictors of the likelihood of receiving HCT. Similarly, in the second model, younger age at enrollment (P o 0.001) and poor risk cytogenetics (P = 0.005) were significantly associated with receipt of HCT. The C-statistic for the model with age+IPSS was 0.706, and the model with age+cytogenetics was 0.695, suggesting that the model with IPSS was a slightly better fit. In a final set of exploratory models including type of provider, QOL was not significant (P40.15 for all domains), and among providers with at least five patients, there were no significant differences in time to HCT between individual leukemia providers (P = 0.86) or between HCT providers (0.61).
Finally, we found no evidence of an association between IPSS and QOL scores, such that IPSS was unlikely to be a confounder in the potential relationship between QOL and time to HCT. Similarly, we found no evidence of an association between ECOG PS and time to HCT, and thus ECOG PS was also unlikely to be a confounder. Multivariable models that included the QOL scores along with IPSS or ECOG PS did not substantially impact the hazard ratios presented for all potential predictors in this analysis including QOL (data not shown). Time from consent (months) Cumulative incidence of receiving HCT Figure 2 . Cumulative incidence of receiving HCT, using a competing risk framework reflecting death without HCT as a competing event.
DISCUSSION
Among medically fit older patients with advanced MDS evaluated at two large MDS centers, the cumulative incidence of RIC HCT was approximately 30% at 6 months and 35% at 1 year post enrollment. Despite significant QOL impairment experienced by many of these patients, their reported QOL at enrollment did not predict the receipt of RIC HCT in multivariable analyses. This was true for overall QOL and several QOL domains, including physical functioning and fatigue. The only factors strongly predicting receipt of HCT were younger age, higher risk cytogenetics and higher IPSS scores. Our data suggest that patient-reported QOL is either not an important consideration for elderly MDS patients and physicians when deciding upon HCT, that the general cancer-related QOL measure we used was not rigorous enough to capture MDS-specific QOL or both.
Our study poses an important question relevant to many decision processes in oncology: should a patient's QOL be a foremost consideration when deciding on pursuing potentially curative therapy? It certainly would make sense to consider QOL if such patient-reported outcomes correlate with survival. Indeed, recent studies have shown that QOL before transplant for hematological malignancies is associated with post transplant mortality even when accounting for patients' performance status and comorbidities. 20, 21 Moreover, patients with advanced solid malignancies place as high a value on optimizing their QOL as to other goals of therapy such as extending their life as much as possible. 29, 30 Our data begs the question whether the possibility of cure that is unique to patients with advanced hematologic malignancies such as high-risk MDS trumps QOL concerns in this population.
MDS is a rare condition that can be somewhat difficult for patients to understand. 31, 32 Perhaps, as a result, one study suggested that approximately half of MDS patients favor a passive role in treatment decision-making, 33 making clinician recommendations the primary driver of most treatment decisions. Our data suggest that QOL concerns may not be routinely incorporated in the treatment decision-making for older patients with MDS. In a prior smaller study of patients with AML (n = 33) and advanced MDS (n = 10), initial QOL was not associated with treatment choice (intensive chemotherapy vs nonintensive chemotherapy/best supportive care). 34 However, 97% of patients reported that QOL was more important to them than length of life, regardless of their choice of therapy. In a more recent study, physicians were found to underestimate the impact of MDS on patients' QOL. 35 These data synergize with ours to suggest that -although important to patients-baseline QOL assessment may not be a significant part of MDS decision-making for elderly patients. Future studies should examine whether integrating formal QOL assessments at the time of HCT consultation could help patients make more informed decisions regarding pursuit of the procedure.
Only about one-third of the medically fit older patients with advanced MDS in our study ultimately underwent HCT. In fact, the rate of HCT for this population is likely much lower when including patients treated at community centers where HCT is not an option. 36 Indeed, a recent population-based study in Minnesota found that, when comparing 33 MDS patients who underwent HCT to 32 age-and risk-matched MDS patient controls, HCT patients were more likely to have a college degree and have a higher income (P = 0.02 for both factors). 17 This disparity is likely due to the fact that referral to tertiary centers such as one of our two facilities is necessary for the procedure; however, our findings suggest that even after such a referral occurs, rates of potentially curative RIC HCT could still be improved. Patient factors, physician QOL and RIC HCT for MDS A El-Jawahri et al factors and donor availability all likely have roles in this disparity. It is also likely that patients' perception of the information relayed to them regarding the risks associated with HCT vs their current QOL has an important role. A challenge to integrating QOL assessment in the treatment patients with MDS is posed by the inherent difficulty of measuring MDS-related QOL. In most MDS-focused studies, including ours, QOL assessment has relied on instruments that are not MDS-specific or have not been validated in this population. 37 Generic cancer instruments such as the EORTC QLQ-C30 may be less sensitive to important domains influencing QOL in MDS. This is a limitation of our methods, and an area for further study. Additionally, with a disease-specific instrument, we would gain a deeper understanding of what constitutes acceptable QOL for patients with MDS, and how they perceive the effect of the illness on their daily life.
Our analysis has additional limitations. First, the MDS-TAO cohort is located at two large tertiary-care centers in Boston, and our findings may thus not be generalizable to patients being treated in other geographical areas. Second, we did not record the consultations between patients and providers, and did not elicit information regarding specific reasons as to why patients did not receive HCT. Therefore, we are unable to comment on specific barriers to HCT or whether patients or clinicians had a dominant role in the HCT decision-making process except to state that we did not find evidence that patient's reported QOL was a barrier. Third, we have a relatively small sample size; on the other hand, this is a rare patient group, and we had enough power to support our conclusions. Next, because patients were screened for relatively good performance status to be eligible for our study, we may have limited the variation in QOL that we were able to observe, especially as we only measured it once (at enrollment). Last, while we did our best to ensure our entry criteria were followed and had almost 100% participation, our analysis may have been susceptible to confounding by intention as well as participant bias.
In conclusion, we found that only a minority of medically fit, transplant-eligible older adults with advanced MDS received RIC HCT for their disease, even at two tertiary academic centers where the procedure is readily available. Moreover, despite the importance of QOL considerations to patients with MDS, patientreported outcomes did not seem to impact the decision to pursue HCT for elderly patients with advanced MDS. Future research should focus on better delineating barriers to HCT in this population, and whether more precise measurement and feedback to patients and providers regarding baseline MDS-specific QOL could be incorporated into the decision-making process.
